RS65202B1 - Supstituisani diaminokarboksamid i diaminokarbonitril pirimidini, njihove kompozicije i postupci za lečenje njima - Google Patents

Supstituisani diaminokarboksamid i diaminokarbonitril pirimidini, njihove kompozicije i postupci za lečenje njima

Info

Publication number
RS65202B1
RS65202B1 RS20240075A RSP20240075A RS65202B1 RS 65202 B1 RS65202 B1 RS 65202B1 RS 20240075 A RS20240075 A RS 20240075A RS P20240075 A RSP20240075 A RS P20240075A RS 65202 B1 RS65202 B1 RS 65202B1
Authority
RS
Serbia
Prior art keywords
mmol
pyrimidine
compound
carboxamide
substituted
Prior art date
Application number
RS20240075A
Other languages
English (en)
Serbian (sr)
Inventor
Brydon L Bennett
Jan Elsner
Paul Erdman
Robert Hilgraf
Laurie Ann Lebrun
Meg Mccarrick
Mehran F Moghaddam
Mark A Nagy
Stephen Norris
David A Paisner
Marianne Sloss
William J Romanow
Yoshitaka Satoh
Jayashree Tikhe
Won Hyung Yoon
Maria Mercedes Delgado
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of RS65202B1 publication Critical patent/RS65202B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
RS20240075A 2011-04-22 2012-04-20 Supstituisani diaminokarboksamid i diaminokarbonitril pirimidini, njihove kompozicije i postupci za lečenje njima RS65202B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161478076P 2011-04-22 2011-04-22
US201161555339P 2011-11-03 2011-11-03
PCT/US2012/034349 WO2012145569A1 (en) 2011-04-22 2012-04-20 Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
EP12718524.7A EP2699553B1 (en) 2011-04-22 2012-04-20 Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
RS65202B1 true RS65202B1 (sr) 2024-03-29

Family

ID=46025954

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20240075A RS65202B1 (sr) 2011-04-22 2012-04-20 Supstituisani diaminokarboksamid i diaminokarbonitril pirimidini, njihove kompozicije i postupci za lečenje njima

Country Status (35)

Country Link
US (7) US9139534B2 (enExample)
EP (2) EP4328223A3 (enExample)
JP (5) JP6027095B2 (enExample)
KR (2) KR101962488B1 (enExample)
CN (5) CN111471021B (enExample)
AR (1) AR087151A1 (enExample)
AU (1) AU2012245387C1 (enExample)
BR (1) BR112013022813B1 (enExample)
CA (1) CA2829264C (enExample)
CL (1) CL2013003025A1 (enExample)
CO (1) CO6821941A2 (enExample)
CR (1) CR20130490A (enExample)
DK (1) DK2699553T3 (enExample)
EC (1) ECSP13012985A (enExample)
ES (1) ES2968700T3 (enExample)
FI (1) FI2699553T3 (enExample)
HR (1) HRP20240097T1 (enExample)
HU (1) HUE064883T2 (enExample)
IL (3) IL228721A (enExample)
LT (1) LT2699553T (enExample)
MX (1) MX351754B (enExample)
NI (1) NI201300113A (enExample)
PE (1) PE20140502A1 (enExample)
PH (2) PH12013501921A1 (enExample)
PL (1) PL2699553T3 (enExample)
PT (1) PT2699553T (enExample)
RS (1) RS65202B1 (enExample)
RU (2) RU2697712C2 (enExample)
SG (2) SG10201702654VA (enExample)
SI (1) SI2699553T1 (enExample)
SM (1) SMT202400031T1 (enExample)
TW (3) TWI548621B (enExample)
UA (1) UA120740C2 (enExample)
WO (1) WO2012145569A1 (enExample)
ZA (1) ZA201306471B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111471021B (zh) 2011-04-22 2024-04-02 西格诺药品有限公司 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法
MX2015005561A (es) * 2012-11-08 2015-07-23 Squibb Bristol Myers Co Compuestos de pirimidina sustituidos con alquil-amida utiles en la modulacion de interleucina 12 (il-12) interleucina 23 (il-23) y/o interferon alfa (ifn alfa).
EP2970104B1 (en) 2013-03-14 2019-04-24 Zeno Royalties & Milestones, LLC Bicyclic analgesic compounds
WO2015039613A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
MX375752B (es) 2013-12-05 2025-03-06 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton.
CN108947867A (zh) 2013-12-12 2018-12-07 卡利拉制药公司 双环烷基化合物及合成
AU2014369031A1 (en) * 2013-12-20 2016-07-07 Signal Pharmaceuticals, Llc Substituted Diaminopyrimidyl Compounds, compositions thereof, and methods of treatment therewith
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
CN113336653A (zh) 2014-03-07 2021-09-03 里科瑞尔姆Ip控股有限责任公司 螺桨烷衍生物及合成
EP3193855B1 (en) 2014-09-17 2021-05-19 Recurium IP Holdings, LLC Bicyclic compounds
ES2972295T3 (es) 2014-12-16 2024-06-12 Signal Pharm Llc Sales de 2-(tert-butilamino)-4-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamida
EP3233808B1 (en) * 2014-12-16 2021-07-14 Signal Pharmaceuticals, LLC Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
MX385379B (es) * 2015-07-24 2025-03-18 Celgene Corp Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilciclohexanol e intermedios utiles en este.
WO2018019244A1 (zh) * 2016-07-27 2018-02-01 广东东阳光药业有限公司 2,6-二甲基嘧啶酮衍生物的盐及其用途
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
US20190231751A1 (en) * 2016-09-12 2019-08-01 Imago Pharmaceuticals, Inc. Treatment of fibrotic disorders with jun n-terminal kinase inhibitors
JP6840853B2 (ja) 2016-12-09 2021-03-10 カディラ・ヘルスケア・リミテッド 原発性胆汁性胆管炎の治療
US11242327B2 (en) 2017-05-15 2022-02-08 Recurium Ip Holdings, Llc Analgesic compounds
IL301709B2 (en) * 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
EP3676297B1 (en) 2017-09-01 2023-05-17 Denali Therapeutics Inc. Compounds, compositions and methods
CN107573249B (zh) * 2017-09-25 2018-12-25 上海馨远医药科技有限公司 一种反式4-烷氧基环己胺的制备方法
SG11202003827YA (en) 2017-11-01 2020-05-28 Bristol Myers Squibb Co Bridged bicyclic compounds as farnesoid x receptor modulators
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
BR112021015639A2 (pt) 2019-02-13 2021-10-05 Denali Therapeutics Inc. Compostos, composições e métodos
CN111718332B (zh) * 2019-03-19 2021-08-17 北京赛特明强医药科技有限公司 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
EP4010324B1 (en) * 2019-08-06 2023-09-06 Eli Lilly and Company Pyrimidine-5-carboxamide compound
CN112574123B (zh) * 2019-09-30 2024-06-11 武汉朗来科技发展有限公司 Jnk抑制剂、其药物组合物和用途
CN116348116A (zh) * 2020-03-06 2023-06-27 台湾卫生研究院 嘧啶化合物及其医药用途
CN113698408B (zh) * 2020-05-22 2025-07-25 武汉朗来科技发展有限公司 Jnk抑制剂、其药物组合物和用途
WO2022048684A1 (zh) * 2020-09-07 2022-03-10 武汉朗来科技发展有限公司 Jnk抑制剂、其药物组合物和用途
WO2022098809A1 (en) * 2020-11-09 2022-05-12 Merck Sharp & Dohme Corp. Diaminopyrimidine carboxamide inhibitors of hpk1
EP4294784A1 (en) * 2021-02-22 2023-12-27 The Trustees of Princeton University 2-substituted bicyclo[1.1.1]pentanes
WO2023108536A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
TW202339749A (zh) 2021-12-16 2023-10-16 大陸商凌科藥業有限公司 Ｔｙｋ２抑制劑及其組合物和方法
CN114315738B (zh) * 2022-01-15 2023-08-18 重庆东寰科技开发有限公司 一种2,4-二氨基嘧啶-3-氧化物的制备方法
WO2024097940A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Therapy for the treatment of cancer
WO2024141066A1 (zh) * 2022-12-30 2024-07-04 杭州矩阵生物药业有限公司 具有jnk抑制活性的嘧啶类衍生物及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH549339A (de) 1971-05-12 1974-05-31 Ciba Geigy Ag Herbizides mittel.
US4301281A (en) * 1979-04-18 1981-11-17 American Home Products Corporation 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]-pyrimidine-6-carboxylic acid amides
DE3338859A1 (de) * 1983-10-26 1985-05-09 Bayer Ag, 5090 Leverkusen Substituierte pyrimidine
DE69839338T2 (de) * 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
EP1054004B1 (en) * 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
ES2310039T3 (es) 1998-05-26 2008-12-16 Warner-Lambert Company Llc Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
EP1184376B1 (en) * 1999-06-09 2005-02-02 Yamanouchi Pharmaceutical Co. Ltd. Novel heterocyclic carboxamide derivatives
JP4622047B2 (ja) 1999-06-09 2011-02-02 アステラス製薬株式会社 新規なヘテロ環カルボキサミド誘導体
AU5108000A (en) 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
DE60006541D1 (de) 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
JP4329290B2 (ja) * 2000-10-06 2009-09-09 田辺三菱製薬株式会社 脂肪族含窒素五員環化合物
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003082855A1 (en) * 2002-03-28 2003-10-09 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
AU2003248246A1 (en) 2002-06-25 2004-01-06 Kyowa Hakko Kogyo Co., Ltd. Hetero-bicyclic compounds
ATE530530T1 (de) * 2002-06-28 2011-11-15 Astellas Pharma Inc Diaminopyrimidincarbonsäureamidderivat
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
AU2003291670A1 (en) * 2002-11-01 2004-06-07 Abbott Laboratories Anti-infective agents
US7902203B2 (en) 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
JPWO2004054617A1 (ja) 2002-12-13 2006-04-20 協和醗酵工業株式会社 中枢疾患の予防および／または治療剤
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
EP1590334B1 (en) * 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
KR100864393B1 (ko) * 2003-04-10 2008-10-20 에프. 호프만-라 로슈 아게 피리미도 화합물
EP1518655A1 (en) * 2003-07-24 2005-03-30 John Palmer Corp. Apparatus for and process of gas-assisted injection molding of plastics material
PT2287156E (pt) 2003-08-15 2013-08-26 Novartis Ag 2,4-di(fenilamino)-pirimidinas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
ATE432077T1 (de) 2003-09-24 2009-06-15 Wyeth Corp 5-arylpyrimidine als anti-krebs-mittel
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
JPWO2005095382A1 (ja) * 2004-03-30 2007-08-16 協和醗酵工業株式会社 抗腫瘍剤
WO2006014482A1 (en) * 2004-07-08 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of pkc-theta
AU2005281735A1 (en) 2004-09-10 2006-03-16 Nycomed Gmbh Ciclesonide and syk inhibitor combination and methods of use thereof
CA2579017A1 (en) 2004-09-10 2006-03-16 Altana Pharma Ag Roflumilast and syk inhibitor combination and methods of use thereof
ES2380631T3 (es) 2004-09-30 2012-05-17 Tibotec Pharmaceuticals Pirimidinas sustituidas en posición 5 inhibidoras de VIH
JP2006124387A (ja) 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
BRPI0609022A2 (pt) 2005-03-10 2010-01-12 Bayer Pharmaceuticals Corp derivados de pirimidina para tratamento de distúrbios hiperproliferativos
MX2008002385A (es) * 2005-08-25 2008-03-18 Hoffmann La Roche Inhibidores de proteinas cinasas activads por mitogenos p38 y metodos para utilizarlos.
WO2007032445A1 (ja) 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
EP1931667A1 (en) * 2005-09-28 2008-06-18 Ranbaxy Laboratories Limited Pyrido-pyridimidine derivatives useful as antiinflammatory agents
US20080318929A1 (en) * 2005-12-21 2008-12-25 Barbosa Antonio J M Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta
EP2046759A1 (en) * 2006-07-21 2009-04-15 Novartis AG 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20080139531A1 (en) 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
DK2146779T3 (en) 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
CA2687943A1 (en) 2007-04-27 2008-11-06 Astrazeneca Ab N'-(phenyl)-n-(morpholin-4-yl-pyridin-2-yl)-pyrimidine-2,4-diamine derivatives as ephb4 kinase inhibitors for the treatment of proliferative conditions
JP2010533700A (ja) 2007-07-16 2010-10-28 アストラゼネカ アクチボラグ ピリミジン誘導体
BRPI0814432A2 (pt) 2007-07-17 2017-05-09 Rigel Pharmaceuticals Inc pirimidinadiaminas substituídas por amina cíclica como inibidores de pkc
KR101773313B1 (ko) * 2008-04-16 2017-08-31 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
WO2009145856A1 (en) * 2008-04-16 2009-12-03 Portola Pharmaceuticals, Inc. 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors
US8063058B2 (en) * 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
WO2009131687A2 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
AU2009239794A1 (en) 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
JP5302389B2 (ja) 2008-04-29 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー Ｊｎｋのピリミジニルピリドンインヒビター
CN102105150B (zh) 2008-05-21 2014-03-12 阿里亚德医药股份有限公司 用作激酶抑制剂的磷衍生物
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ624345A (en) 2008-06-27 2016-07-29 Celgene Avilomics Res Inc 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR20110049902A (ko) * 2008-09-01 2011-05-12 아스텔라스세이야쿠 가부시키가이샤 2,4-디아미노피리미딘 화합물
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
MX2011002825A (es) 2008-09-18 2011-04-05 Astellas Pharma Inc Compuestos heterociclicos de carboxamida.
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
EP2344502A2 (en) * 2008-10-22 2011-07-20 F. Hoffmann-La Roche AG Pyrimidinyl pyridone inhibitors of jnk
BRPI0919885A2 (pt) 2008-10-31 2015-08-11 Centocor Ortho Biotech Inc Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática
WO2010067886A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivative
US8809538B2 (en) 2009-01-12 2014-08-19 Array Biopharma Inc. Piperidine-containing compounds and use thereof
CN102348707A (zh) 2009-01-13 2012-02-08 葛兰素集团有限公司 作为syk激酶抑制剂的嘧啶甲酰胺衍生物
US8377924B2 (en) * 2009-01-21 2013-02-19 Rigel Pharmaceuticals Inc. Protein kinase C inhibitors and uses thereof
TW201040162A (en) 2009-05-06 2010-11-16 Portola Pharm Inc Inhibitors of JAK
JP2012148977A (ja) 2009-05-20 2012-08-09 Astellas Pharma Inc アミノシクロヘキシルアルキル基を有する２，４−ジアミノピリミジン化合物
AU2010258937A1 (en) * 2009-06-08 2012-01-19 Reduction Technologies Inc. Systems, methods and devices for correcting spinal deformities
JP2012529522A (ja) * 2009-06-10 2012-11-22 アボット・ラボラトリーズ キナーゼ阻害剤としての２−（１ｈ−ピラゾール−４−イルアミノ）−ピリミジン
JP2012197231A (ja) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
WO2011065800A2 (ko) * 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
JP5802677B2 (ja) 2009-12-01 2015-10-28 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびその使用
JP2011173853A (ja) * 2010-02-26 2011-09-08 Astellas Pharma Inc 置換アミノアダマンチルアルキル基を有する２，４−ジアミノピリミジン化合物
JP6035238B2 (ja) 2010-07-21 2016-11-30 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびその使用
US20130237493A1 (en) 2010-09-30 2013-09-12 Portola Pharmaceuticals, Inc. Combination therapy of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
US20130244963A1 (en) 2010-09-30 2013-09-19 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
CN111471021B (zh) * 2011-04-22 2024-04-02 西格诺药品有限公司 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法
AU2014369031A1 (en) * 2013-12-20 2016-07-07 Signal Pharmaceuticals, Llc Substituted Diaminopyrimidyl Compounds, compositions thereof, and methods of treatment therewith
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
ES2972295T3 (es) * 2014-12-16 2024-06-12 Signal Pharm Llc Sales de 2-(tert-butilamino)-4-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamida
EP3233808B1 (en) * 2014-12-16 2021-07-14 Signal Pharmaceuticals, LLC Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin

Also Published As

Publication number Publication date
RU2017121958A (ru) 2019-01-29
KR102055532B1 (ko) 2019-12-12
SG10201702654VA (en) 2017-06-29
US11325890B2 (en) 2022-05-10
AU2012245387C1 (en) 2016-05-05
IL252952A0 (en) 2017-08-31
US20180305322A1 (en) 2018-10-25
CA2829264C (en) 2020-04-07
RU2017121958A3 (enExample) 2019-01-29
JP7374955B2 (ja) 2023-11-07
US10266500B2 (en) 2019-04-23
US20170267647A1 (en) 2017-09-21
US9139534B2 (en) 2015-09-22
CN105001165A (zh) 2015-10-28
JP6898961B2 (ja) 2021-07-07
KR20140027160A (ko) 2014-03-06
MX2013010946A (es) 2013-12-16
TWI599563B (zh) 2017-09-21
US20150336901A1 (en) 2015-11-26
US12129237B2 (en) 2024-10-29
LT2699553T (lt) 2024-02-12
CO6821941A2 (es) 2013-12-31
AU2012245387A1 (en) 2013-03-28
JP2023179797A (ja) 2023-12-19
SI2699553T1 (sl) 2024-03-29
TWI548621B (zh) 2016-09-11
JP2021138755A (ja) 2021-09-16
JP2014514322A (ja) 2014-06-19
HUE064883T2 (hu) 2024-04-28
CN103492370A (zh) 2014-01-01
MX351754B (es) 2017-10-27
PT2699553T (pt) 2024-01-24
PH12015501677A1 (en) 2015-10-05
IL228721A (en) 2016-06-30
CN106946795A (zh) 2017-07-14
IL228721A0 (en) 2013-12-31
KR101962488B1 (ko) 2019-03-26
BR112013022813B1 (pt) 2022-04-19
KR20190029772A (ko) 2019-03-20
US10040770B2 (en) 2018-08-07
TW201736348A (zh) 2017-10-16
PE20140502A1 (es) 2014-05-02
ECSP13012985A (es) 2013-11-29
US20230116093A1 (en) 2023-04-13
FI2699553T3 (fi) 2024-01-24
CN111471021A (zh) 2020-07-31
US20190194144A1 (en) 2019-06-27
US20130029987A1 (en) 2013-01-31
NI201300113A (es) 2014-02-25
SMT202400031T1 (it) 2024-03-13
AR087151A1 (es) 2014-02-26
JP6502302B2 (ja) 2019-04-17
EP2699553B1 (en) 2023-11-08
CN111499580A (zh) 2020-08-07
CL2013003025A1 (es) 2014-05-30
SG194086A1 (en) 2013-11-29
PH12015501677B1 (en) 2015-10-05
IL245792B (en) 2018-03-29
ZA201306471B (en) 2014-12-23
AU2012245387B2 (en) 2015-07-09
RU2625309C2 (ru) 2017-07-13
CR20130490A (es) 2014-01-14
DK2699553T3 (da) 2024-01-29
JP6027095B2 (ja) 2016-11-16
NZ614776A (en) 2015-06-26
WO2012145569A1 (en) 2012-10-26
CN105001165B (zh) 2020-06-23
US10919865B2 (en) 2021-02-16
JP2017002091A (ja) 2017-01-05
UA120740C2 (uk) 2020-02-10
PH12013501921A1 (en) 2013-11-25
US20210114992A1 (en) 2021-04-22
IL252952B (en) 2020-02-27
TW201311651A (zh) 2013-03-16
CN106946795B (zh) 2020-06-02
EP4328223A3 (en) 2024-11-06
RU2697712C2 (ru) 2019-08-19
ES2968700T3 (es) 2024-05-13
JP2019112457A (ja) 2019-07-11
TW201627291A (zh) 2016-08-01
RU2013152021A (ru) 2015-05-27
PL2699553T3 (pl) 2024-03-25
CN103492370B (zh) 2016-10-26
CN111471021B (zh) 2024-04-02
HRP20240097T1 (hr) 2024-03-29
US9701643B2 (en) 2017-07-11
TWI681952B (zh) 2020-01-11
BR112013022813A2 (pt) 2016-08-02
EP4328223A2 (en) 2024-02-28
EP2699553A1 (en) 2014-02-26
IL245792A0 (en) 2016-06-30
CA2829264A1 (en) 2012-10-26

Similar Documents

Publication Publication Date Title
US12129237B2 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
HK40108423A (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
AU2015201030B2 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
AU2016244228B2 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
NZ614776B2 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith